Dr. Reznik is a computational oncologist who is also affiliated with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the Urology Service. His research applies computational and informatic approaches to address basic and translational questions in mitochondrial genetics and metabolic dysregulation in cancer. The long-term goal of his research program is understanding how metabolic phenomena support the initiation, progression, and therapeutic susceptibility of tumors. Originally trained as an engineer, he has applied tools from optimization theory to develop predictive, genome-scale models of bacterial and eukaryotic metabolism from high-throughput metabolic data. Using data from The Cancer Genome Atlas Consortium, Dr. Reznik produced the first large-scale assessment of mitochondrial DNA copy number variation across solid tumor types. In parallel, he has developed integrative informatic approaches to study solid tumor metabolism through analysis of metabolomic and transcriptomic data, including the publication of the first atlas of metabolomic changes across tumor types. He is also an active member of the Kidney Cancer Working Group and contributes to the analysis of genomic, metabolomic, and immunological data related to kidney cancer biology and therapy.